16-ketoestradiol
Description
## 16-ketoestradiol: A Key Player in Estrogen Metabolism and Research
16-ketoestradiol (16-oxoestradiol) is a **metabolite of estradiol**, the most potent naturally occurring estrogen in humans. This means it is a derivative of estradiol, formed through a specific chemical modification. Specifically, 16-ketoestradiol arises from the oxidation of estradiol at the 16-position.
**Why is 16-ketoestradiol important for research?**
16-ketoestradiol is garnering increasing attention due to its potential role in various biological processes, including:
**1. Estrogen Metabolism and Signaling:**
* 16-ketoestradiol is a potent estrogen, and its **interaction with estrogen receptors** is a key area of research. Understanding its role in estrogen signaling pathways can shed light on its physiological functions and potential implications in health and disease.
* Studying 16-ketoestradiol can help elucidate the **complex interplay of different estrogen metabolites** in the body, particularly in the context of **hormonal regulation and reproductive health.**
**2. Neuroprotective Effects:**
* Preliminary research suggests that 16-ketoestradiol possesses **neuroprotective properties**, potentially contributing to its role in **cognitive function** and **neurological health**.
* Investigating its mechanisms of action in the brain could lead to new therapeutic strategies for neurodegenerative diseases like Alzheimer's and Parkinson's.
**3. Cardiovascular Health:**
* 16-ketoestradiol has shown potential **cardiovascular benefits** in some studies, including **anti-inflammatory and anti-atherosclerotic effects.**
* Further research is needed to fully understand its impact on cardiovascular health and to explore its potential as a therapeutic target for heart disease.
**4. Cancer Research:**
* The potential role of 16-ketoestradiol in **estrogen-dependent cancers** like breast and ovarian cancer is being investigated.
* Understanding how 16-ketoestradiol interacts with estrogen receptors in these cancers could lead to novel strategies for prevention and treatment.
**5. Other Potential Benefits:**
* 16-ketoestradiol has been associated with **bone health** and **immune function**, further highlighting its broad impact on human health.
**In Summary:**
16-ketoestradiol is a fascinating molecule with a growing list of potential biological roles. Research into this compound holds promise for advancing our understanding of estrogen metabolism, unraveling its impact on various physiological processes, and potentially discovering new therapeutic avenues for a range of health conditions.
16-ketoestradiol: RN given refers to (17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 66417 |
| CHEMBL ID | 1627347 |
| CHEBI ID | 34165 |
| SCHEMBL ID | 928512 |
| MeSH ID | M0044623 |
Synonyms (42)
| Synonym |
|---|
| 566-75-6 |
| estra-1,5(10)-trien-16-one, 3,17-dihydroxy-, (17.beta.)- |
| nsc-51169 |
| nsc51169 |
| 16-ketoestradiol |
| 16-oxo-17beta-estradiol |
| (17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-one |
| (8r,9s,13s,14s,17r)-3,17-dihydroxy-13-methyl-7,8,9,11,12,14,15,17-octahydro-6h-cyclopenta[a]phenanthren-16-one |
| LMST02010047 |
| CHEMBL1627347 |
| chebi:34165 , |
| unii-6ce096rr70 |
| nsc 51169 |
| 6ce096rr70 , |
| 16-oxoestradiol |
| estra-1,3,5(10)-triene-3beta,17beta-diol-16-one |
| estra-1,3,5(10)-trien-16-one, 3,17-dihydroxy-, (17beta)- |
| SCHEMBL928512 |
| 3,17-dihydroxyestra-1,3,5(10)-trien-16-one # |
| KJDGFQJCHFJTRH-YONAWACDSA-N |
| estra-1,3,5(10)-trien-16-one, 3,17-dihydroxy-, (17.beta.)- |
| (17r)-3,17.beta.-dihydroxy-1,3,5(10)-estratriene-16-one |
| 3,17.beta.-dihydroxyestra-1,3,5(10)-trien-16-one |
| 16-keto-17.beta.-estradiol |
| estra-1,3,5(10)-trien-16-one, 3,17.beta.-dihydroxy- |
| DTXSID5040386 |
| J108.088A , |
| 16-keto-17beta-estradiol |
| 16-keto-estriol |
| 16-oxo-17b-estradiol |
| 16-keto-17b-estradiol |
| 16-oxoestradiol-17b |
| 1,3,5(10)-estratriene-3,17b-diol-16-one |
| 3,17b-dihydroxyestra-1,3,5(10)-trien-16-one |
| 3,17beta-dihydroxyestra-1,3,5(10)-trien-16-one |
| Q27115859 |
| 16-keto-17- beta -estradiol |
| 16-keto 17?-estradiol |
| 16-keto 17beta-estradiol |
| 16-keto-17-beta-estradiol |
| PD053504 |
| (1r,3as,3br,9bs,11as)-1,7-dihydroxy-11a-methyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-2-one |
Drug Classes (1)
| Class | Description |
|---|---|
| 16-oxo steroid | Any oxo steroid carrying an oxo group at position 16. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID55149 | The compound was tested in vitro for its ability to initiate DNA replication | 1998 | Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9 | Effect of steroids on DNA synthesis in an in vitro replication system: initial quantitative structure-activity relationship studies and construction of a non-estrogen receptor pharmacophore. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (60.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.06
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (6.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||